Lang GE, et al. - The objectives of this study are to evaluate effectiveness and safety of intravitreal ranibizumab 0.5 mg plus laser (COMBI) versus laser monotherapy (LASER) in patients with visual impairment because of diabetic macular oedema (DME) in either nonproliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR) and to examine the relevance of inner versus outer retinal thickness. This investigation demonstrated that ranibizumab plus laser is a significant treatment alternative for the management of DME. Patients with DME in PDR might also benefit from combined therapy compared to laser alone.